Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

ENSAT Stage I Adrenal Cortex Carcinoma 1

Interventions

Carboplatin 133pembrolizumab 132Cisplatin 120Paclitaxel 104Gemcitabine 88Specimen Handling 82Magnetic Resonance Spectroscopy 82Docetaxel 74Dexamethasone 60Cyclophosphamide 60Pemetrexed 57Bevacizumab 56durvalumab 55Capecitabine 55Doxorubicin 52Radiotherapy 51Oxaliplatin 50Fluorouracil 49Radiation 48Leucovorin 44Rituximab 43Vincristine 42Lenalidomide 40Etoposide 39atezolizumab 37Nivolumab 37Letrozole 36130-nm albumin-bound paclitaxel 32Prednisone 31Irinotecan 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Mitotane × 90 days × Clear all
NCT03583710 2026-04-07

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

M.D. Anderson Cancer Center

Phase 3 Recruiting
240 enrolled

ENSAT Stage I Adrenal Cortex Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡